The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases
Open accessAbstract
Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti‐VEGF‐A monotherapy efficacy by targeting both VEGF‐A and angiopoietin‐2 (ANG‐2), a factor strongly upregulated in vitreous fluids of patients with retinal vascular disease and exerting some of its activities in concert with VEGF‐A. Simultaneous VEGF‐A and ANG‐2 inhibition was found to reduce vessel lesion number, permeability, retinal edema, and neuron loss more effectively than either agent alone in a spontaneous choroidal neovascularization (CNV) model. We describe the generation of a bispecific domain‐exchanged (crossed) monoclonal antibody (CrossMAb; RG7716) capable of binding, neutralizing, and depleting VEGF‐A and ANG‐2. RG7716 showed greater efficacy than anti‐VEGF‐A alone in a non‐human primate laser‐induced CNV model after intravitreal delivery. Modification of RG7716's FcRn and FcγR binding sites disabled the antibodies' Fc‐mediated effector functions. This resulted in increased systemic, but not ocular, clearance. These properties make RG7716 a potential next‐generation therapy for neovascular indications of the eye. The ratio of angiopoietins ANG‐1 and ANG‐2 regulates vessel quiescence and neoangiogenesis as well as barrier function. It also acts as a switch from health to neovascular eye diseases. The ratio of angiopoietins ANG‐1 and ANG‐2 regulates vessel quiescence and neoangiogenesis as well as barrier function. It also acts as a switch from health to neovascular eye diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis
Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., & Yancopoulos, G. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81813-9 · Cited by 2,847
Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., & Qin, Y. (1995) · Nature · doi:10.1038/376070a0 · Cited by 1,820
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Angiopoietin-1 protects the adult vasculature against plasma leakage
Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N., Holash, J., McDonald, D. M., & Yancopoulos, G. D. (2000) · Nature Medicine · doi:10.1038/74725 · Cited by 1,297
Dumont, D. J., Gradwohl, G., Fong, G. H., Puri, M. C., Gertsenstein, M., Auerbach, A., & Breitman, M. L. (1994) · Genes & Development · doi:10.1101/gad.8.16.1897 · Cited by 985
Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., et al. (2006) · Nature Medicine · doi:10.1038/nm1351 · Cited by 933
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Nishijima, K., Ng, Y.-S., Zhong, L., Bradley, J., Schubert, W., Jo, N., Akita, J., Samuelsson, S. J., Robinson, G. S., Adamis, A. P., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.061237 · Cited by 707
Self-citationAsahara, T., Chen, D., Takahashi, T., Fujikawa, K., Kearney, M., Magner, M., Yancopoulos, G. D., & Isner, J. M. (1998) · Circulation Research · doi:10.1161/01.res.83.3.233 · Cited by 683
Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells
Patsch, C., Challet-Meylan, L., Thoma, E. C., Urich, E., Heckel, T., O’Sullivan, J. F., Grainger, S. J., Kapp, F. G., Sun, L., Christensen, K., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3205 · Cited by 629
Ho, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 590
Puri, M. C., Rossant, J., Alitalo, K., Bernstein, A., & Partanen, J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00276.x · Cited by 519
Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 482
Self-citationSaharinen, P., Eklund, L., Miettinen, J., Wirkkala, R., Anisimov, A., Winderlich, M., Nottebaum, A., Vestweber, D., Deutsch, U., Koh, G. Y., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1715 · Cited by 471
Campochiaro, P. A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-0993-5 · Cited by 386
Diabetic Retinopathy: Targeting Vasoregression
Hammes, H.-P., Feng, Y., Pfister, F., & Brownlee, M. (2011) · Diabetes · doi:10.2337/db10-0454 · Cited by 347
Funatsu, H., Yamashita, H., Ikeda, T., Mimura, T., Eguchi, S., & Hori, S. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00568-2 · Cited by 346
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346
Kabat, E. A., & Wu, T. T. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.5.1709 · Cited by 333
Jo, N., Mailhos, C., Ju, M., Cheung, E., Bradley, J., Nishijima, K., Robinson, G. S., Adamis, A. P., & Shima, D. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050588 · Cited by 322
Self-citation(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/j.ohc.2006.05.009 · Cited by 299
Chang, T. S. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.11.1460 · Cited by 239
Watanabe, D., Suzuma, K., Suzuma, I., Ohashi, H., Ojima, T., Kurimoto, M., Murakami, T., Kimura, T., & Takagi, H. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.10.004 · Cited by 209
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Self-citationAngiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis
Ziegler, T., Horstkotte, J., Schwab, C., Pfetsch, V., Weinmann, K., Dietzel, S., Rohwedder, I., Hinkel, R., Gross, L., Lee, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66549 · Cited by 191
Angiopoietin-2 Is Critical for Cytokine-Induced Vascular Leakage
Benest, A. V., Kruse, K., Savant, S., Thomas, M., Laib, A. M., Loos, E. K., Fiedler, U., & Augustin, H. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070459 · Cited by 178
The Angiopoietin/Tie-2 System Regulates Pericyte Survival and Recruitment in Diabetic Retinopathy
Cai, J., Kehoe, O., Smith, G. M., Hykin, P., & Boulton, M. E. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1206 · Cited by 164
Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice
Meyer, T. V., Robles-Carrillo, L. D., Robson, T., Länger, F. P., DESAI, H., Davila, M., Amaya, M., Francis, J. L., & Amirkhosravi, A. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03212.x · Cited by 160
Angiopoietin 2 Induces Pericyte Apoptosis via α3β1 Integrin Signaling in Diabetic Retinopathy
Park, S. W., Yun, J.-H., Kim, J. H., Kim, K.-W., Cho, C., & Kim, J. H. (2014) · Diabetes · doi:10.2337/db13-1942 · Cited by 157
Kümpers, P., Gueler, F., David, S., Slyke, P. V., Dumont, D., Park, J.-K., Bockmeyer, C. L., Parikh, S. M., Pavenstädt, H. J., Haller, H. G., et al. (2011) · Critical Care · doi:10.1186/cc10523 · Cited by 151
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
Schlothauer, T., Rueger, P., Stracke, J. O., Hertenberger, H., Fingas, F., Kling, L., Emrich, T., Drabner, G., Seeber, S., Auer, J., et al. (2013) · mAbs · doi:10.4161/mabs.24981 · Cited by 146
Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2–Tie2 complex
Barton, W. A., Tzvetkova-Robev, D., Miranda, E. P., Kolev, M. V., Rajashankar, K. R., Himanen, J. P., & Nikolov, D. B. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1101 · Cited by 134 · cited 2×
“We therefore used the angiopoietin receptor-binding domains (RBDs) as a Fc fusion protein (Barton et al, 2006).”
Oshima, Y., Oshima, S. M., Nambu, H., Kachi, S., Takahashi, K., Umeda, N., Shen, J., Dong, A., Apte, R. S., Duh, E. J., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2209fje · Cited by 132
Julien, S., Biesemeier, A., Taubitz, T., & Schraermeyer, U. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304019 · Cited by 127
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
Kim, H., Robinson, S. B., & Csaky, K. G. (2009) · PubMed Central · Cited by 119
Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood–retinal barrier
Nambu, H., Nambu, R., Oshima, Y., Hackett, S. F., Okoye, G., Wiegand, S. J., Yancopoulos, G. D., Zack, D. J., & Campochiaro, P. A. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302230 · Cited by 115
Hartnett, M. E., Martiniuk, D., Byfield, G. E., Geisen, P., Zeng, G., & Bautch, V. L. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-1780 · Cited by 110
Angiopoietin‐2 enhances retinal vessel sensitivity to vascular endothelial growth factor
Oshima, Y., Deering, T. G., Oshima, S. M., Nambu, H., Reddy, P. S., Kaleko, M., Connelly, S., Hackett, S. F., & Campochiaro, P. A. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.10442 · Cited by 108
Proteomics of Vitreous Humor of Patients with Exudative Age-Related Macular Degeneration
Koss, M., Hoffmann, J., Nguyen, N., Pfister, M., Mischak, H., Mullen, W., Husi, H., Ręjdak, R., Koch, F., Jankowski, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096895 · Cited by 105
Self-citationLoukovaara, S., Robciuc, A., Holopainen, J. M., Lehti, K., Pessi, T., Liinamaa, J., Kukkonen, K.-T., Jauhiainen, M., Koli, K. M., Keski‐Oja, J., et al. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2012.02473.x · Cited by 101
How do angiopoietins Tie with vascular endothelial growth factors?
Saharinen, P., Bry, M., & Alitalo, K. K. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283386673 · Cited by 91
Regulation of signaling events involved in the pathophysiology of neovascular AMD.
Wang, H., & Hartnett, M. E. (2016) · PubMed Central · Cited by 89
Structural basis for angiopoietin-1–mediated signaling initiation
Yu, X., Seegar, T. C. M., Dalton, A. C., Tzvetkova‐Robev, D., Goldgur, Y., Rajashankar, K. R., Nikolov, D. B., & Barton, W. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216890110 · Cited by 76
Menden, H. L., Welak, S. R., Cossette, S. M., Ramchandran, R., & Sampath, V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.600692 · Cited by 73
Angiopoietin-1 Suppresses Choroidal Neovascularization and Vascular Leakage
Lee, J., Park, D. Y., Park, D. Y., Park, I., Chang, W., Nakaoka, Y., Komuro, I., Yoo, O.-J., & Koh, G. Y. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-13897 · Cited by 73
Cahoon, J. M., Rai, R. R., Carroll, L. S., Uehara, H., Zhang, X., O’Neil, C. L., Medina, R. J., Das, S. K., Muddana, S. K., Olson, P. R., et al. (2015) · Diabetes · doi:10.2337/db14-1030 · Cited by 64
Chapter 6 Ocular Models of Angiogenesis
Aguilar, E., Dorrell, M. I., Friedlander, D. F., Jacobson, R., Johnson, A. J., Marchetti, V., Moreno, S. K., Ritter, M. R., & Friedlander, M. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(08)02806-1 · Cited by 60
Nagai, N., von Leithner, P. L., Izumi‐Nagai, K., Hosking, B. M., Chang, B., Hurd, R. E., Adamson, P., Adamis, A. P., Foxton, R. H., Ng, Y., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-13989 · Cited by 56
Self-citationNambu, H., Umeda, N., Kachi, S., Oshima, Y., Akiyama, H., Nambu, R., & Campochiaro, P. A. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20292 · Cited by 56
Increased VEGF‐A promotes multiple distinct aging diseases of the eye through shared pathomechanisms
Marneros, A. G. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505613 · Cited by 55
Wu, F. T. H., Lee, C. R., Bogdanovic, E., Prodeus, A., Gariépy, J., & Kerbel, R. S. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404193 · Cited by 44
Stubenrauch, K. G., Wessels, U., Essig, U., Kowalewsky, F., Vogel, R., & Heinrich, J. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.08.023 · Cited by 24
Self-citationLambert, N. G., Zhang, X., Rai, R. R., Uehara, H., Choi, S., Carroll, L. S., Das, S. K., Cahoon, J. M., Kirk, B. H., Bentley, B. M., et al. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.01.009 · Cited by 19
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“However, faricimab, a bispecific antiVEGF/Ang2 antibody, was reported to have greater efficacy than anti-VEGF alone in a non-human primate laser-induced CNV model (Regula et al., 2016) and has been compared to ranibizumab in phase II studies.”
MethodBispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00010-1 · Cited by 785
Self-citationTherapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Diabetic retinopathy: Looking forward to 2030
Tan, T.-E., & Wong, T. Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1077669 · Cited by 511
Metadata
- Authors
- Regula, J. T., Lundh von Leithner, P., Foxton, R., Barathi, V. A., Cheung, C. M. G., Bo Tun, S. B., Wey, Y. S., Iwata, D., Dostalek, M., Moelleken, J., Stubenrauch, K. G., Nogoceke, E., Widmer, G., Strassburger, P., Koss, M. J., Klein, C., Shima, D. T., & Hartmann, G.
- Venue
- EMBO Molecular Medicine
- Published
- 2016-10-14
- Volume
- 8
- Issue
- 11
- Pages
- 1265-1288
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2531065411
- Cited by
- 376
- References
- 56
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.